A condom and a tubal ligation device have almost nothing in common as products — one is a single-use barrier, the other a permanent implant. Under MDR Annex VIII, Rule 15, both are classified by the same rule, and both are the worked examples MDCG 2021-24 uses to show how far apart Rule 15's outcomes can land: Class IIb for one, Class III for the other. The question that separates them has nothing to do with contraceptive mechanism and everything to do with one narrower test.
A purpose-based rule, not a mechanism-based one
Most of Annex VIII's 22 classification rules sort devices by invasiveness, duration of contact, or anatomical target. Rule 15 sorts by intended purpose first: it catches any device specifically intended for contraception or for preventing the transmission of sexually transmitted diseases, independent of how the device achieves that purpose. A hormonal implant, a barrier device, and a permanent sterilization device can all be caught by the same rule despite sharing almost no design or mechanism of action — the common thread is the stated intended purpose, which is exactly why the rule's default-plus-exception structure has to do the rest of the sorting work on its own.
The exception is doing all the work
Because Rule 15's baseline is a single default class, the entire classification outcome for a given device rests on one downstream question: is it implantable, or is it a long-term invasive device? A device that is neither stays at the Class IIb default. A device that is either one moves straight to Class III, with no intermediate step. There is no partial credit in Rule 15's structure — a device does not land in Class IIa for being less invasive than a true implant, or in a notional Class IIb-plus for being invasive but not permanent. It is binary, and manufacturers who assume a non-implantable device is automatically the lower class should confirm that the device does not independently qualify as long-term invasive before relying on that assumption.
- Implantable devices intended for contraception or STI prevention go to Class III under Rule 15 regardless of how the device otherwise performs its function.
- Long-term invasive devices — not implanted, but intended for sustained internal placement — carry the same Class III outcome as true implants under this rule.
- Everything else meeting Rule 15's intended-purpose test defaults to Class IIb, which is itself a meaningfully higher baseline than the Class I or IIa outcomes some non-invasive device categories receive elsewhere in Annex VIII.
- Devices caught by more than one rule — a Rule 15 purpose combined with, for example, a software or energy-delivery function — take whichever rule's outcome produces the highest class, not Rule 15's outcome by default.
Rule 15 does not ask how the device prevents pregnancy or infection. It asks how long the device stays inside the body once it is there. Why the implantable test, not the mechanism, decides the class
Where this actually bites manufacturers
The practical risk sits with devices near the implantable/long-term-invasive boundary rather than with the clear cases at either end. A vaginal ring replaced monthly, an intrauterine system intended for multi-year use, or a subdermal rod are all closer to that line than a single-use barrier device, and the classification file needs to document the duration-of-use and removability analysis that supports whichever side of the line the manufacturer lands on — not just assert the conclusion. This is squarely the kind of determination that belongs inside a broader women's health regulatory strategy, since contraceptive and STI-prevention devices rarely move through development in isolation from the therapeutic-area considerations — combination-product questions, labeling under pregnancy and lactation frameworks, post-market surveillance expectations — that a notified body will also be weighing.
- State the intended purpose precisely. Contraception or STI-prevention claims trigger Rule 15 regardless of mechanism — write the intended purpose the way it will appear in labeling, not a looser marketing description.
- Document the implantable/long-term-invasive determination. Show the duration-of-use and removability analysis, not just the conclusion.
- Screen for overlapping rules. Energy-delivery, software, or drug-device combination elements can bring in another Annex VIII rule with a higher resulting class.
- Scope the conformity assessment route early. A Class III outcome changes the conformity assessment route and notified body engagement timeline well before the technical file is finalized.
Compare Rule 15's structure with Rule 14's ancillary-substance test or Rule 18's tissue-derivative default, and the pattern across Annex VIII's special rules becomes clear: each one picks a single decisive variable and lets it override the device's broader design. For Rule 15, that variable is implantable or long-term invasive status. Get the duration-of-use analysis right, and the rest of the classification file follows from it.
Frequently asked questions
What devices fall under MDR Rule 15?
Rule 15 of Annex VIII, Chapter III applies to devices specifically intended to be used for contraception or the prevention of the transmission of sexually transmitted diseases. That intended purpose, not the device's mechanism of action, is what brings a device into Rule 15's scope in the first place.
When does a contraceptive device move from Class IIb to Class III?
Rule 15's default classification is Class IIb. It rises to Class III when the device is implantable or is a long-term invasive device. MDCG 2021-24 gives condoms as a Class IIb example under Rule 15 and tubal ligation devices as a Class III example, illustrating exactly that split.
Does Rule 15 apply if another classification rule also applies to the same device?
It can. A device can fall within more than one classification rule's scope at once, and MDR Annex VIII's general classification rules direct manufacturers to apply the rule that produces the highest resulting class when more than one rule applies. Confirm with your notified body which other rules might read onto a specific device design before finalizing a Rule 15-only classification file.
Sources & further reading
- EUR-Lex. Regulation (EU) 2017/745, Annex VIII, Chapter III (Classification Rules). eur-lex.europa.eu
- European Commission, MDCG. MDCG 2021-24 Rev.1 — Guidance on classification of medical devices under Regulation (EU) 2017/745. health.ec.europa.eu
This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm current MDR Rule 15 classification practice with your notified body, the relevant competent authority, or qualified counsel before acting.